Why Sarepta Therapeutics Inc Stock Is Crashing Today
Shares of clinical-stage biotech Sarepta Therapeutics fell by nearly 40% this morning. Here's why.
Why I Won't Buy Ebola Stocks
The share prices of companies leading the fight against Ebola have been soaring lately. Is this investor enthusiasm justified?
Could Sarepta Therapeutics Inc. Be Running Out of Money?
A biotech stock running out of money is a worry that healthcare investors don't take lightly. Let's take a closer look at clinical-stage drug developer Sarepta Therapeutics and discover whether or not it has enough cash in its coffers to execute on its business strategy.